ProKidney has developed a cell-based product called REACT (Renal Autologous Cell Therapy), designed to build renal function in patients with chronically diseased kidneys.
Over 500,000 patients per year suffer from diabetic kidney disease in the United States.
ProKidney is currently conducting multiple Phase 2 clinical trials for its REACT product. The ProKidney Phase 2 clinical trials are based on a successful internationally conducted Phase 1 clinical trial of the REACT product. Some of the first patients to be injected have been followed for over three years and remain dialysis-free. The trial demonstrated that REACT was well tolerated by patients with moderate to severe diabetic kidney disease.